Phase II, randomized, placebo-controlled clinical trial designed to assess feasibility, safety, and effect of investigational autologous bone marrow-derived mesenchymal stem cells (MSCs) and c-kit+ cardiac stem cells (CSCs) both alone and in combination (Combo), compared to placebo as well as each other, administered by NOGA injection in subjects with ischemic cardiomyopathy.
Post TAVR patients
To assess whether an investigational rivaroxaban-based anticoagulation strategy, following TAVR, compared to an antiplatelet-based strategy is superior in reducing death or first thromboembolic events (DTE).
Heart Failure; Cardiac Failure; Congestive Heart Failure; Heart Failure Left-Sided
The purpose of the study is to evaluate the safety and effectiveness of the ReliantHeart HeartAssist 5® VAD System in patients listed for heart transplantation and at risk of death from refractory end-stage heart failure.
Aortic Valve Stenosis
To evaluate the safety and effectiveness of the Model 400 aortic valve bioprosthesis.
Persistent Atrial Fibrillation; Arrhythmias
The purpose of this study is to demonstrate the safety and effectiveness of the investigational THERMOCOOL SMARTTOUCH® SF catheter in the treatment of drug refractory symptomatic persistent atrial fibrillation (PsAF) following standard electrophysiology mapping and RF ablation procedures.
Anthracycline induced cardiomyopathy
Safety and feasibility study of delivering investigational allogeneic human mesenchymal stem cells (allo-MSCs) via NOGA to cancer survivors with left ventricular (LV) dysfunction secondary to anthracycline-induced cardiomyopathy (AIC).
Multi center, randomized controlled study, to determine if a significant decrease in the rate of heart failure re-hospitalizations occurs during a follow-up period when investigational ReDS guided treatment is used as an adjunct to standard of care.
Severe Mitral Regurgitation
The purpose of this expanded clinical study is to evaluate the performance and safety of the investigational Tendyne Mitral Valve System in severe mitral regurgitation in patients with functional disability greater than or equal to NYHA Class II, who are not suitable candidates for surgical replacement with otherwise available devices.
Mitral Valve Insufficiency
Non-randomized pilot study to evaluate the safety and performance of the investigational Medtronic Twelve Intrepid TMVR System in high risk patients with severe, symptomatic mitral regurgitation.
Myocardial Infarction; Heart Failure; Left Ventricular Remodeling
Evaluate the safety and feasibility of investigational VentriGel delivered via endomyocardial injections using NOGA mapping/Myostar catheter to subjects with left ventricular ejection fraction (LVEF) 25 to 45% secondary to MI. Secondary endpoints will look at efficacy variables of ESV, EDV, EF, scar mass.